UCB to Double Down in Rare Disease With $2.5 Billion Ra Deal

(Bloomberg) -- UCB SA agreed to buy Ra Pharmaceuticals Inc. for about $2.5 billion to join forces with one of its largest competitors in developing a rare-disease medicine, the field behind many re...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.